Company profile

Ticker
VERU
Exchange
CEO
Mitchell Shuster Steiner
Employees
Incorporated in
Location
Fiscal year end
Former names
Female Health Co
SEC CIK
IRS number
391144397

VERU stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

8 Aug 19
11 Dec 19
30 Sep 20

News

Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Dec 18 Sep 18
Revenue 9.73M 6.98M 6.37M 5.2M
Net income -2.77M -4.03M -2.15M -7.92M
Diluted EPS -0.04 -0.06 -0.03 -0.14
Net profit margin -28.52% -57.83% -33.72% -152%
Operating income -1.84M -2.12M -1.01M -3.77M
Net change in cash 2.14M -3.08M 5.22M -1.82M
Cash on hand 8.04M 5.9M 8.98M 3.76M
Cost of revenue 3.16M 2.37M 1.73M 2.01M
Annual (USD) Sep 18 Sep 17 Sep 16 Sep 15
Revenue 15.86M 13.66M 22.13M 32.6M
Net income -23.94M -6.61M 344.73K 4.35M
Diluted EPS -0.44 -0.25 0.01 0.15
Net profit margin -151% -48.42% 1.56% 13.33%
Operating income -20.87M -8.49M 3.02M 6.62M
Net change in cash 481.91K 892.52K -1.72M -1.69M
Cash on hand 3.76M 3.28M 2.39M 4.11M
Cost of revenue 7.08M 6.64M 8.78M 13.63M

Financial data from Veru earnings reports

Financial report summary

?
Competition
CanadaAllerganHCIPathAllergan
Management Discussion
  • The Company generated net revenues of $9.7 million and net loss of $2.8 million, or $(0.04) per basic and diluted common share, for the three months ended June 30, 2019, compared to net revenues of $5.5 million and net loss of $7.9 million, or $(0.15) per basic and diluted common share, for the three months ended June 30, 2018. Net revenues increased 77% for the period.   
  • FC2 net revenues represented 95% of total net revenues. FC2 net revenues increased 69% for the period. There was a 9% increase in total FC2 unit sales and an increase in FC2 average sales price per unit of 56%. The increase in the FC2 average sales price per unit compared to the same period last year was due to the increase in sales in the U.S. prescription channel. The Company experienced an increase in FC2 net revenues of 1,074% in the U.S. prescription channel and a slight decrease in global public sector net revenues of 4%.
  • Cost of sales increased to $3.2 million in the three months ended June 30, 2019 from $2.4 million for the same period last year primarily due to the increase in unit sales in the U.S. prescription channel.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: administered, appeal, beneficial, bureaucratic, carrier, create, depot, export, GnRH, grow, injection, LHRH, loading, noncash, OTC, peptide, political, preNDA, prevail, problem, recharacterization, repeated, slight, summer, surge, testosterone, volume
Removed: activity, American, ASCO, bioequivalence, bisindole, blocking, breast, Domestic, educate, HeyDoctor, human, merit, organization, ovarian, paclitaxel, pancreatic, pathway, referenced, release, sex, Society, student, tablet, Timm, transmission, transmitting, triple, variety, Zika